PharmacoEconomics & Outcomes News 792, p35 - 2 Dec 2017 NICE recommends palbociclib and ribociclib for breast cancer In draft guidance, the UK National Institute for Health and Care Excellence (NICE) recommends palbociclib (Ibrance) and ribociclib (Kisqali) for the treatment of locally advanced, hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, or secondary breast cancer. Both drugs were recommended for routine access within the National Health Service after their drug manufacturers (Pfizer and Novartis, respectively) agreed to reduce their prices. The drugs appear to increase progression-free survival by approximately 10 months, and may reduce chemotherapy requirements. They are both administered orally, once daily, in combination with an aromatase inhibitor. "The committee heard that by postponing disease progression, palbociclib and ribociclib may reduce the number of people who are exposed to the often unpleasant side effects of chemotherapy, and delay the need for its use in others," said Professor Carole Longson, director of the centre for health technology evaluation at NICE. "We are pleased therefore that the companies have been able to agree reductions to the price of palbociclib and ribociclib to allow them to be made routinely available to people with this type of breast cancer," she added. NICE. Breast cancer patients to have routine access to two life extending drugs after new deal, say NICE in draft guidance Internet Document : 16 Nov 2017. Available from: URL: https://www.nice.org.uk/news/article/breast-cancer-patients- to-have-routine-access-to-two-life-extending-drugs-after-new-deal-say-nice-in-draft- guidance 803283868 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud